Highlights
- •Rituximab (RTX) is considered to be an efficient and safe treatment for neuromyelitis optica (NMO).
- •Capillary leak syndrome (CLS) can be secondary to some medications.
- •There are only two fatal complications in NMO patient treated with RTX reported.
- •One case of CLS in NMO patient after rituximab treatment is presented.
- •Relationship between RTX and CLS causation is suggested.
Abstract
61-year-old woman with Neuromyelitis optica (NMO) diagnosis treated with rituximab
was referred to our hospital with severe hypovolemic shock and anasarca. The laboratory
findings showed marked hemoconcentration and a decrease in total serum protein. She
developed a multiple organ failure and died three hours later. We diagnosed the patient
as having capillary leak syndrome (CLS). CLS is a very rare condition caused by unexplained
episodic capillary hyperpermeability, which can be idiopathic or secondary to some
conditions like infection, malignant disease and some drugs like monoclonal antibodies.
We reported the first CLS case in NMO patient treated with rituximab.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Multiple Sclerosis and Related DisordersAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- An update on the evidence for the efficacy and safety of rituximab in the management of neuromyelitis optica.Ther. Adv. Neurol. Disord. 2016; 9: 180-188
- Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients.Arch. Neurol. 2008; 65: 1443-1448
- Clinical review: serious adverse events associated with the use of rituximab - a critical care perspective.Crit. Care. 2012; 16: 231
- Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab.Neurology. 2011; 76: 1310-1315
- Capillary leak syndrome: etiologies, pathophysiology, and management.Kidney Int. 2017;
Yardimci B., Kazancioglu R., 2016. Idiopathic systemic capillary leak syndrome: a case report. Iran Red Crescent Med J [Internet]. Feb 20 (cited 2017 May 7);18(2). Available from: 〈http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4867362/〉.
Article info
Publication history
Published online: June 06, 2017
Accepted:
June 5,
2017
Received:
May 21,
2017
Footnotes
☆All authors have read the manuscript and approved its submission. The manuscript is not under review at any other publication. All the authors confirm that have no conflict of interest.
Identification
Copyright
© 2017 Elsevier B.V. All rights reserved.
